Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study: Results from the Targeted Agent and Profiling Utilization Registry Study

  • Apar K. Ganti
  • , Michael Rothe
  • , Pam K. Mangat
  • , Elizabeth Garrett-Mayer
  • , Elie G. Dib
  • , Herbert L. Duvivier
  • , Eugene R. Ahn
  • , Deepti Behl
  • , Hossein Borghaei
  • , Ani S. Balmanoukian
  • , Anu Gaba
  • , Rui Li
  • , Kwabena Osei-Boateng
  • , Ramya Thota
  • , Gina N. Grantham
  • , Abigail Gregory
  • , Susan Halabi
  • , Richard L. Schilsky

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study: Results from the Targeted Agent and Profiling Utilization Registry Study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science